Page 977 - Read Online

Page 10 of 12 Lonardo et al. Hepatoma Res 2020;6:83 I http://dx.doi.org/10.20517/2394-5079.2020.89

REFERENCES
1. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention
and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604.
2. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced
liver disease. Gastroenterology 2009;136:138-48.
3. Pennisi G, Celsa C, Giammanco A, Spatola F, Petta S. The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease:
screening issue and future perspectives. Int J Mol Sci 2019;20:5613.
4. Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United
Kingdom, and United States for the period 2016-2030. J Hepatol 2018;69:896-904.
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology
2004;127:S35-50.
6. Diehl AM, Goodman Z, Ishak KG. Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced
liver injury. Gastroenterology 1988;95:1056-62.
7. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and
future directions. Dig Liver Dis 2017;49:471-83.
8. Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic
steatohepatitis. Clin Liver Dis 2018;22:1-10.
9. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, et al. Sex and gender: modifiers of health, disease, and medicine. Lancet 2020;396:565-82.
10. Lonardo A, Nascimbeni F, Ballestri S, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of
research gaps. Hepatology 2019;70:1457-69.
11. Balakrishnan M, Patel P, Dunn-Valadez S, et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of
progression vs men: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2020; doi: 10.1016/j.cgh.2020.04.067.
12. Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational
research. J Clin Med 2020;9:1278.
13. McGlynn KA, Petricka JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional
variability. Clin Liver Dis 2015;19:223-38.
14. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73.e1.
15. Petrick JL, Braunlin M, Laversanne M, Valery P, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by
histologic subtype, 1978-2007. Int J Cancer 2016;139:1534-45.
16. Yang D, Hanna DL, Usher J, et al. Impact of sex on the survival of patients with hepatocellular carcinoma: a surveillance, epidemiology,
and end results analysis. Cancer 2014;120:3707-16.
17. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular
carcinoma. Clin Gastroenterol Hepatol 2011;9:428-33; quiz e450.
18. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology 2004;127:S87-96.
19. An J, Chang S, Kim HI, Song GW, Shim JH. The clinical behavior and survival of patients with hepatocellular carcinoma and a family
history of the disease. Cancer Med 2019;8:6624-33.
20. Gellert-Kristensen H, Richardson TG, Davey Smith G, Nordestgaard BG, Tybjaerg-Hansen A, Stender S. Combined effect of PNPLA3,
TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 2020; doi:
10.1002/hep.31238.
21. Dragani TA. Risk of HCC: genetic heterogeneity and complex genetics. J Hepatol 2010;52:252-7.
22. Jang HJ, Yang HR, Ko JS, Moon JS, Chang JY, Seo JK. Development of hepatocellular carcinoma in patients with glycogen storage
disease: a single center retrospective study. J Korean Med Sci 2020;35:e5.
23. Santella RM, Wu HC. Environmental exposures and hepatocellular carcinoma. J Clin Transl Hepatol 2013;1:138-43.
24. Ng AWT, Poon SL, Huang MN, et al. Aristolochic acids and their derivatives are widely implicated in liver cancers in Taiwan and
throughout Asia. Sci Transl Med 2017;9:eaan6446.
25. Yao KF, Ma M, Ding GY, et al. Meta-analysis reveals gender difference in the association of liver cancer incidence and excess BMI.
Oncotarget 2017;8:72959-71.
26. Chen CL, Kuo MJ, Yen AM, et al. Gender difference in the association between metabolic factors and hepatocellular carcinoma. JNCI
Cancer Spectr 2020;4:pkaa036.
27. Borena W, Strohmaier S, Lukanova A, et al. Metabolic risk factors and primary liver cancer in a prospective study of 578,700 adults. Int J
Cancer 2012;131:193-200.
28. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic
evidence. Clin Gastroenterol Hepatol 2006;4:369-80.
29. Non-alcoholic Fatty Liver Disease Study Group, Lonardo A, Bellentani S, et al. Epidemiological modifiers of non-alcoholic fatty liver
disease: Focus on high-risk groups. Dig Liver Dis 2015;47:997-1006.
30. Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and
reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv Ther
2017;34:1291-326.
31. Petroni ML, Brodosi L, Marchignoli F, Musio A, Marchesini G. Moderate alcohol intake in non-alcoholic fatty liver disease: to drink or
not to drink? Nutrients 2019;11:E3048.